Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries Ltd. (TEVA), Wednesday said that the U.S. Food and Drug Administration (FDA) has approved Ajovy for the prevention of episodic migraine in patients aged 6-17 years.
Ajovy was first approved in 2018 for the preventive treatment of migraine in adults.
For comments and feedback contact: editorial@rttnews.com
Business News
April 24, 2026 15:15 ET Economics news flow was relatively light this week even as the conflict in the Middle East continued, raising concerns for policymakers. In the U.S., spending data, initial jobless claims and pending home sales were the highlights. Business confidence in the biggest euro area economy was in focus in Europe. Inflation data from Japan gained attention in Asia.